3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
1331
Breast Neoplasms
687
Carcinoma, Non-Small-Cell Lung
543
Neoplasm Metastasis
436
Lymphoma
435
Leukemia, Myeloid, Acute
432
Melanoma
402
Prostatic Neoplasms
380
Multiple Myeloma
366
Lymphoma, Non-Hodgkin
356
Ovarian Neoplasms
343
Colorectal Neoplasms
333
Precursor Cell Lymphoblastic Leukemia-Lymphoma
328
Pancreatic Neoplasms
328
Leukemia, Lymphocytic, Chronic, B-Cell
323
Leukemia
282
Lung Neoplasms
275
Glioblastoma
267
Unspecified Adult Solid Tumor, Protocol Specific
257
Recurrence
253
Lymphoma, Follicular
248
Lymphoma, Large B-Cell, Diffuse
245
Brain Neoplasms
232
Lymphoma, Mantle-Cell
210
Hodgkin Disease
193
Carcinoma, Renal Cell
193
Head and Neck Neoplasms
192
Myelodysplastic Syndromes
187
Glioma
172
Burkitt Lymphoma
172
Interventions
pembrolizumab
1
binimetinib
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Completed
×
Spinocerebellar Degenerations
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts